Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald upped their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an overweight rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Trading Down 2.2 %

Shares of VNDA opened at $4.85 on Friday. The firm’s fifty day simple moving average is $5.34 and its two-hundred day simple moving average is $5.14. Vanda Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $6.75. The stock has a market capitalization of $282.26 million, a P/E ratio of -60.63 and a beta of 0.77.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. The company had revenue of $50.47 million for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. As a group, research analysts predict that Vanda Pharmaceuticals will post -0.49 EPS for the current fiscal year.

Institutional Trading of Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Aristides Capital LLC acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at about $272,000. GSA Capital Partners LLP increased its holdings in Vanda Pharmaceuticals by 39.8% during the 4th quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 161,737 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in Vanda Pharmaceuticals by 17.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 431,224 shares of the biopharmaceutical company’s stock worth $1,772,000 after purchasing an additional 64,670 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Vanda Pharmaceuticals by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 4,387 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Vanda Pharmaceuticals by 70.1% in the first quarter. BNP Paribas Financial Markets now owns 101,363 shares of the biopharmaceutical company’s stock valued at $417,000 after purchasing an additional 41,767 shares in the last quarter. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.